 |
 |
 |
 |
 |
 |
 |
|
|
 |
  |
 |
 |
 |
 |
 |
 |
 |
 |
| First-In-Class Blood test for Major Depressive Disorder |  |
 |
"As a practicing psychiatrist I believe that the MDDScore™ blood test will have a significant effect on the psychiatric industry. Currently, one of our greatest challenges in the field of psychiatry is the absence of objective tests to help us with the diagnosis of this disorder. " (Psychiatrist)
"A Psychiatrist’s diagnosis for major depressive disorder is usually based on a series of clinical questions, and clinical assessments, which may cause patients difficulty in validating their disorder. " (Psychiatrist) Ridge Diagnostics is a neurodiagnostic company offering its proprietary first-in-class blood test for Major Depressive Disorder (MDD) through its CLIA certified laboratory in North Carolina. Based upon its proprietary Human Biomarker Library and its Biomarker Hyper-Map™ technology platform, Ridge Diagnostics has developed multi-variant biological maker assays and diagnostic algorithms to diagnose, select and monitor treatment for MDD and other neuropsychiatric disorders. Antidepressant drugs are the most frequently prescribed medication in the US today where depression strikes over 19 million adults each year – more than coronary artery disease, cancer or AIDS. For the first time, objective biological test information about depression may aid physicians in the differential diagnosis of MDD, the selection of proper treatment and effective management of their patients. Map Key: District of Columbia (DC), Puerto Rico (PR), US Virgin Islands (USVI)  
|
 |
2013 Ridge Diagnostics, Inc. announces MDDScore™ - First Blood Test for Depression at the American Psychiatric Association Annual Meeting May 18-21, 2013 San Francisco, CA Ridge Diagnostics, Inc. Presents Clinical Data on Blood Test for Depression at 68th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry May 16-18, 2013 San Francisco, CA Ridge Diagnostics, Inc. CEO spoke at The 6th Annual OneMedForum January 7-9, 2013 San Francisco, CA 2012 Ridge Diagnostics' poster “A Multi-Analyte Biomarker Approach for the Detection of Depression in a Clinical Population with Comorbid Pain” won second place at the recent Neuroscience Education Institute’s Congress. The associated abstract was featured in CNS Spectrums®. December 2012 U.S. Psychiatric and Mental Health Congress November 8-11, 2012 San Diego, CA NEI Global Psychopharmacology Congress October 18-21, 2012 San Diego, CA NCDEU Annual Meeting May 29-June 1, 2012 Phoenix, AZ 2011 American College of Neuropsychopharmacology 50th Annual Meeting December 4-8, 2011 Waikaloa Beach, Hawaii House Oversight and Government Reform Subcommittee on TARP and Financial Services November 7, 2011 Washington, DC U.S. Psychiatric and Mental Health Congress November 7-10, 2011 Las Vegas, Nevada American Academy of Pain Management 22nd Annual Clinical Meeting September 20-23, 2011 Las Vegas, Nevada PAINWeek September 7-10, 2011 Las Vegas, Nevada Veterans Health Administration Mental Health Conference—Improving Veterans Mental Health Care for the 21st Century Baltimore, Maryland August 23-25, 2011 NCDEU Annual Meeting June 13-16, 2011 Boca Raton, Florida American Psychiatric Association 164th Annual Meeting May 14-18, 2011 Honolulu, Hawaii Society of Biological Psychiatry 66th Annual Meeting May 12-14, 2011 San Francisco, California Ridge Diagnostics, Inc. CEO spoke at Neurotech Investing and Partnering Conference May 9-10, 2011 San Diego, CA "Biology vs. Psychology" discussed depression and the availability of the MDDScore. February 19, 2011 2010 2009 |
![Patients ask [for diagnostic blood test] all the time, ‘Is there a blood test for this?’ All the time. Every day. There’s a big interest. - Psychiatris](images/collage.jpg)
